Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | DRD4 | P21917 | 4/20 | 0.65 |
| ▸ | DRD2 | P14416 | 3/20 | 0.65 |
| ▸ | DRD3 | P35462 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | SOD1 | P00441 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6030381 | 0.98 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2KDM4EDRD4DRD2 | |
| Bromide SCHEMBL6579961 | 0.88 | SIGMAR1 (0.60) | ALDH1A1SMN1; SMN2KDM4EDRD4DRD2 | |
| SCHEMBL6030554 | 0.87 | SIGMAR1 (0.62) | ALDH1A1SMN1; SMN2KDM4EDRD4DRD2 | |
| SCHEMBL28432321 | 0.86 | MAPT (0.64) | ALDH1A1SMN1; SMN2DRD2MAPTMEN1 | |
| SCHEMBL6030916 | 0.86 | MAPT (0.83) | ALDH1A1SMN1; SMN2KDM4EDRD4DRD2 | |
| SCHEMBL28313258 | 0.85 | MAPT (0.68) | ALDH1A1SMN1; SMN2KDM4EDRD2MAPT | |
| SCHEMBL11549500 | 0.85 | SIGMAR1 (0.60) | ALDH1A1SMN1; SMN2KDM4EDRD4DRD2 | |
| SCHEMBL5542069 | 0.85 | DRD4 (0.66) | ALDH1A1SMN1; SMN2KDM4EDRD4DRD2 | |
| SCHEMBL5542061 | 0.85 | SIGMAR1 (0.60) | ALDH1A1SMN1; SMN2KDM4EDRD4DRD2 | |
| SCHEMBL11923385 | 0.85 | SIGMAR1 (0.79) | ALDH1A1SMN1; SMN2DRD4DRD2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0960106-B1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORP (US) | 2004-05-06 | — | — | EP | claimed |
| US-20030119851-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-06-26 | — | — | US | claimed |
| US-20020007064-A1 | 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | THURKAUF ANDREW (US) | 2002-01-17 | — | — | US | claimed |
| JP-2001521492-A | — | — | 2001-11-06 | — | — | JP | claimed |
| EP-0960106-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1999-12-01 | — | — | EP | claimed |
| US-5859246-A | TREATING NEUROPSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION (US) | 1999-01-12 | — | — | US | claimed |
| WO-1998033784-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1998-08-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007064-A1 | 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | HTR2C, GRIN2C, HTR1A | SIGMAR1 91/4885ALDH1A1 422/4885SMN1; SMN2 2966/4885 |
| US-20030119851-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | HTR2C, GRIN2C, HTR1A | SIGMAR1 91/4885ALDH1A1 422/4885SMN1; SMN2 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.